A Case Control Study on the Contribution of Factor V-Leiden, Prothrombin G20210A, and MTHFR C677T Mutations to the Genetic Susceptibility of Deep Venous Thrombosis

Wassim Y. Almawi1, Hani Tamim2, Raghid Kreidy3, Georgina Timson1, Elias A. Rahal3, Malak Nabulsi4, Ramzi R. Finan3, Noha Irani-Hakime3
1Al-Jawhara Center for Molecular Medicine, Genetics, and Inherited Diseases, Arabian Gulf University, Manama, Bahrain
2Faculty of Health Sciences, American University of Beirut, Beirut
3St. Georges University Hospital, Beirut
4Islamic Hospital, Tripoli, Lebanon

Tóm tắt

Từ khóa


Tài liệu tham khảo

Rosendaal F.R. Venous thrombosis: A multicausal disease. Lancet 1999;353:1167–1173.

Bertina RM, Koeleman BPC, Koster T, et~al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64–67.

Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504–1508.

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698–3703.

Tamim H, Finan RR, Almawi WY. Prevalence of two thrombophilia predisposing mutations: Factor V G1691A (R506Q; Leiden) and prothrombin G20210A, among healthy Lebanese. Thromb Haemost 2002;88:691–692.

Zivelin A, Griffin JH, Xu X, et~al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood 1997;89:397–402.

Almawi WY, Ameen G, Tamim H, Finan RR, Irani-Hakime N, Factor V. prothrombin G20210A, and methylenetetrahydrofolate reductase [MTHFR] C677T gene polymorphism in angiographically documented coronary artery disease. J Thrombosis Thrombolysis 2004;17:199–205.

Couturaud F, Oger E, Abalain JH, et~al. Methylenetetrahydrofolate reductase C677T genotype and venous thrombo-embolic disease. Respiration 2000;67:657–661.

Shmeleva VM, Kapustin SI, Papayan LP, Sobczynska-Malefora A, Harrington DJ, Savidge GF. Prevalence of hyperhomocysteinemia and the MTHFR C677T polymorphism in patients with arterial and venous thrombosis from North Western Russia. Thromb Res 2003;111:351–356.

Ray JG, Shmorgun D, Chan, WS. Common C677T polymorphism of the methylene-tetrahydrofolate reductase gene and the risk of venous thromboembolism: Meta-analysis of 31 studies. Pathophysiol Haemost Thromb 2002;32:51–58.

Zalavras ChG, Giotopoulou S, Dokou E, et~al. Lack of association between the C677T mutation in the 5,10-methylenetetrahydrofolate reductase gene and venous thromboembolism in Northwestern Greece. Int Angiol 2002;21:268–271.

De Stefano V, Casorelli I, Rossi E, Zappacosta B, Leone G. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Semin Thromb Hemost 2000;26:305–311.

Morelli VM, Lourenco DM, D’Almeida V, et~al. Hyperhomocysteinemia increases the risk of venous thrombosis independent of the C677T mutation of the methylenetetrahydrofolate reductase gene in selected Brazilian patients. Blood Coagul Fibrinolysis 2002;13:271–275.

Keijzer MB, den Heijer M, Blom HJ, et~al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolate-reductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002;88:723–728.

Gemmati D, Serino ML, Moratelli S, Tognazzo S, Ongaro A, Scapoli GL. Coexistence of factor V G1691A and factor II G20210A gene mutations in a thrombotic family is associated with recurrence and early onset of venous thrombosis. Haemostasis 2001;31:99–105.

Hatzaki A, Anagnostopoulou E, Metaxa-Mariatou V, et~al. The impact of heterozygosity for the factor V Leiden and factor II G20210A mutations on the risk of thrombosis in Greek patients. Int Angiol 2003;22:79–82.

Aznar J, Vaya A, Estelles A, et~al. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives. Haematologica 2000;85:1271–1276.

Emmerich J, Rosendaal FR, Cattaneo M, et~al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism–pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809–816.

Salomon O, Steinberg DM, Zivelin A, et~al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: Prevalence and risk assessment. Arterioscler Thromb Vasc Biol 1999;19:511–518.

Cattaneo M, Tsai MY, Bucciarelli P, et~al. A common mutation in the methylenetetrahydrofolate reductase gene (C677T) increases the risk for deep-vein thrombosis in patients with mutant factor V (factor V:Q506). Arterioscler Thromb Vasc Biol 1997;17:1662–1666.

Fujimura H, Kawasaki T, Sakata T, et~al. Common C677T polymorphism in the methylenetetrahydrofolate reductase gene increases the risk for deep vein thrombosis in patients with predisposition of thrombophilia. Thromb Res 2000;98:1–8.

Rintelen C, Mannhalter C, Lechner K, et~al. No evidence for an increased risk of venous thrombosis in patients with factor V Leiden by the homozygous 677 C to T mutation in the methylene-tetrahydrofolate-reductase gene. Blood Coagul Fibrinolysis 1999;10:101–105.

Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol 2000;65:45–49.

Taher A, Khalil I, Shamseddine A, El-Ahdab F, Bazarbachi A. High prevalence of Factor V Leiden mutation among healthy individuals and patients with deep venous thrombosis in Lebanon: Is the eastern Mediterranean region the area of origin of this mutation? Thromb Haemost 2001;86:723–724.

De Stefano V, Rossi E, Paciaroni K, et~al. Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene. Haematologica 2003;88:61–66.

Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222–1231.

Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell 1993;72:477–481.

Simioni P, Prandoni P, Lensing AW, et~al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood 2000;96:3329–3333.

Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of anticoagulation. Thromb Haemost 1999;81:684–689.

Folsom AR, Cushman M, Tsai MY, Heckbert SR, Aleksic N. Prospective study of the G20210A polymorphism in the prothrombin gene, plasma prothrombin concentration, and incidence of venous thromboembolism. Am J Hematol 2002;71:285–290.

Margaglione M, Brancaccio V, Giuliani N, et~al. Increased risk for venous thrombosis in carriers of the prothrombin G → A20210 gene variant. Ann Intern Med 1998; 129:89–93.

Vargas M, Soto I, Pinto CR, et~al. The prothrombin 20210A allele and factor V Leiden are associated with venous thrombosis but not with early coronary artery disease. Blood Coagul Fibrinolysis 1999;10:39–41.

Isotalo PA, Donnelly JG. Prevalence of methylenetetrahydrofolate reductase mutations in patients with venous thrombosis. Mol Diagn 2000;5:59–66.

Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998;79:254–258.

Margaglione M, D’Andrea G, D’Addedda M, et~al. The methylenetetrahydrofolate reductase TT677 genotype is associated with venous thrombosis independently of the coexistence of the FV Leiden and the prothrombin A20210 mutation. Thromb Haemost. 1998;79:907–911.

Makris M, Preston FE, Beauchamp NJ, et~al. Co-inheritance of the 20210A allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb Haemost. 1997;78:1426–1429.

Howard TE, Marusa M, Boisza J, et~al. The prothrombin gene 3′-untranslated region mutation is frequently associated with factor V Leiden in thrombophilic patients and shows ethnic-specific variation in allele frequency. Blood 1998;91:1092.

Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133–1134.

Zama T, Murata M, Ono F, et~al. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals. Int J Haematol 1996;65:71–78.

Arruda VR, Annichino-Bizzacchi JM, Goncalves MS, Costa FF. Prevalence of the prothrombin gene variant (nt20210A) in venous thrombosis and arterial disease. Thromb Haemost 1997;78:1430–1433.

Rosendaal FR, Doggen CJM, Zivelin A, et~al. Geographic distribution of the 20210G to A prothrombin variant. Thromb Haemost 1998;79:706–708.

Zoller B, Norlund L, Leksell H, et~al. High prevalence of the FV R506Q mutation causing APC resistance in a region of southern Sweden with a high incidence of venous thrombosis. Thromb Res 1996;83:475–477.